Axon Enterprise - AXON Stock Forecast, Price & News

Axon Enterprise, Inc. develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, TASER, and Software and Sensors. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence. Its products include TASER 7, TASER X26P, TASER X2, TASER Consumer devices, and related cartridges; on-officer body cameras, Axon Fleet in-car systems, and other devices; Axon Evidence digital evidence management software; Axon Signal enabled devices, as well as hardware extended warranties; and Axon docks, cartridges, and batteries. It sells its products through its direct sales force, distribution partners, online store, and third-party resellers. Axon Enterprise, Inc. has a strategic partnership with Fusus, Inc. to expand the capabilities of Axon Respond and the Fusus Real Time Crime Center in the Cloud solution to provide agencies real-time operations situational awareness, including streamlined investigative workflows. The company was formerly known as TASER International, Inc. and changed its name to Axon Enterprise, Inc. in April 2017. Axon Enterprise, Inc. was incorporated in 1993 and is headquartered in Scottsdale, Arizona.

Axon Enterprise Stock Down 1.6 %

AXON Stock traded down $1.97 during trading on Friday, hitting $124.10. 346,773 shares of the stock traded hands, compared to its average volume of 302,220. The firm's 50 day moving average is $98.17 and its two-hundred day moving average is $112.58. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.70 and a quick ratio of 2.18. The stock has a market cap of $8.82 billion, a price-to-earnings ratio of 63.64 and a beta of 0.66. Axon Enterprise has a 1 year low of $82.49 and a 1 year high of $209.00.

Axon Enterprise (NASDAQ:AXON - Get Rating) last released its earnings results on Tuesday, August 9th. The biotechnology company reported $0.44 EPS for the quarter, topping analysts' consensus estimates of $0.39 by $0.05. The company had revenue of $285.61 million for the quarter, compared to analysts' expectations of $258.96 million. Axon Enterprise had a net margin of 14.20% and a return on equity of 12.57%. The firm's revenue was up 30.5% compared to the same quarter last year. During the same quarter last year, the business earned ($0.72) EPS. On average, sell-side analysts anticipate that Axon Enterprise will post 1.35 EPS for the current year.

Analysts Set New Price Targets

AXON has been the topic of a number of research analyst reports. Robert W. Baird dropped their target price on shares of Axon Enterprise from $145.00 to $125.00 in a report on Wednesday, May 11th. Morgan Stanley downgraded shares of Axon Enterprise from an "overweight" rating to an "equal weight" rating and set a $120.00 price target for the company. in a research note on Monday, May 23rd. StockNews.com upgraded shares of Axon Enterprise from a "hold" rating to a "buy" rating in a report on Saturday, June 18th. Northland Securities reduced their price objective on shares of Axon Enterprise from $180.00 to $130.00 in a report on Thursday, May 12th. Finally, Credit Suisse Group raised their price target on shares of Axon Enterprise from $134.00 to $142.00 and gave the company an "outperform" rating in a research report on Wednesday. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $163.25.

Insider Activity at Axon Enterprise

In related news, Director Mark W. Kroll sold 3,159 shares of the firm's stock in a transaction on Wednesday, June 8th. The shares were sold at an average price of $102.82, for a total value of $324,808.38. Following the completion of the transaction, the director now directly owns 13,691 shares of the company's stock, valued at $1,407,708.62. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 6.90% of the stock is currently owned by insiders.